Fusion dual-tracer SPECT-based hepatic dosimetry predicts outcome after radioembolization for a wide range of tumour cell types.

Eur J Nucl Med Mol Imaging · 2015 · PMC4480819 · PMID 25916740

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Response rates at 3 months (64 % versus 35 %; P = 0.069) and 6 months (78 % versus 40 %; P = 0.064) showed a trend in favour of glass microspheres, but survival showed no difference (heavily biased by HCC).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.